Astrazeneca Stock News

AstraZeneca's (AZN) sBLA seeks approval of Enhertu for unresectable and/or metastatic HER2-positive metastatic breast cancer previously treated with an anti-HER2-based regimen.

Los Angeles, USA, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Parkinson''s Disease Pipeline Offers Promising New Options for Treatment | DelveInsight DelveInsight''s "Parkinson''s Disease Pipeline Insight" report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the Parkinson''s Disease pipeline landscapes. The report comprises Parkinson''s Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Parkinson''s Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Parkinson''s Disease pipeline products. Some of the key takeaways from the Parkinson''s Disease Pipeline Report Major Parkinson''s Disease companies such as Cerevel Therapeutics, Abbvie, Pharma Two B, Roche, Kissei Pharmaceutical, Peptron, Inc., Lundbeck A/S, AstraZeneca, Nobilis Therapeutics, Treefrog Therapeutics, Cantabio Pharmaceuticals, Anavex Life Sciences, Ipsen, Prevail Therapeutics, AFFiRiS, Sio Gene Therapies, UCB Pharma, Brain Neurotherapy Bio, Inc., Neuraly, Inc., NeuroDerm, BlueRock Therapeutics, Sun Pharma Advanced Research Company, Xoc Pharmaceuticals, Hong Kong WD Pharmaceutical, 1ST Biotherapeutics, Inc., Biogen, Denali Therapeutics, Inhibikase Therapeutics,Cerevance, Aspen Neuroscience,Prilenia Therapeutics,Cortexyme Inc.,Gain Therapeutics, Clexio Biosciences, Orpheris, Inc., Alkahest, Inc., and others are developing potential drug candidates to improve the Parkinson''s Disease treatment scenario.

Ultomiris could be just months away from its third approved indication in the U.S.

AstraZeneca PLC (LSE:AZN) said its Enhertu treatment has been granted Priority Review by the US Food and Drug Administration (FDA) for patients with HER2-positive metastatic breast cancer treated wit

Pieris Is A Biotech To Watch With Extensive Pipeline And Key Partnerships

A safety panel of the European Medicines Agency ((EMA)) has recommended the addition of a rare spinal inflammation called transverse myelitis to the product information of the

Data from multiple studies support the use of AstraZeneca's (AZN) COVID vaccine booster against several variants of concern, including Omicron.

European Medicines Agency''s safety committee also recommended a similar warning to be included for Johnson & Johnson''s one shot Covid vaccine.

Amgen (AMGN) and AstraZeneca (AZN) announce TEZSPIRE (tezepelumab-ekko) is now available for shipment to wholesalers in the U.S.TEZSPIRE was approved by the FDA on Dec

AstraZeneca Plc (NASDAQ: AZN ) said the U.S. government has agreed to purchase an additional 500,000 doses of its antibody cocktail, Evusheld, used to prevent COVID-19. The Company said the delivery of the doses was expected in Q1 of 2022, and more details about the deal would Full story available on Benzinga.com

AstraZeneca Plc (NASDAQ: AZN ) has posted preliminary data from an ongoing safety and immunogenicity trial of its COVID-19 shot, Vaxzevria. When given as a third booster dose, the data showed that it generated a higher antibody response against the omicron variant and others, including Beta, Delta, Alpha, and Gamma. The increased response was seen in people who were previously vaccinated with either Full story available on Benzinga.com

AstraZeneca (AZN) collaborates with Scorpion Therapeutics to discover, develop and commercialize precision medicines against previously hard-to-target cancer proteins, with the

Positive results from a preliminary analysis of an ongoing trial showed that AstraZeneca''s (AZN) Vaxzevria (ChAdOx1-S [Recombinant]), when given as a third dose booster, increased

Drug-maker to submit data to regulators worldwide given urgent need for boosters

AstraZeneca says early trial findings support the shot's use as a booster no matter the shot used for primary vaccination.